Back

Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma

Cardiovascular Research

25 April 2020
Organised by: Logo
Read full article
ESC Journals

Contributors

Carlos G Santos-Gallego
Carlos G Santos-Gallego

Author

Mount Sinai School of Medicine New York , United States of America

Juan Badimon
Juan Badimon

Author

Icahn School of Medicine at Mount Sinai New York City , United States of America

You may be interested in
thumbnail
Congress Presentation
When should prolonged antiplatelet regimens be considered?
26 August 2023
thumbnail
Congress Presentation
Optimizing post-PCI therapy: ticagrelor, prasugrel, clopidogrel, and cilostazol reduce early MACE
21 March 2026
thumbnail
Congress Presentation
New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group
28 August 2021
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources